24 July 2012
Russian Nanotechnologies, the state- run technology holding, and Domain Associates, a U.S. venture fund, are investing about $40 million in San Diego-based biopharmaceutical company CoDa Therapeutics.
The deal is the first joint investment between Domain Associates and Rusnano, as the company is known, according to an e-mailed press release. Domain is an investor in CoDa. Rusnano will invest through a subsidiary.
Rusnano teamed up with Domain Associates in March to invest $760 million in U.S. life science companies and build facilities in Russia. The companies plan to invest in about 20 U.S.-based health-care technology companies involved in pharmaceuticals, biotechnology and medical devices, the Moscow-based company said in March.
PrintOctober 10 – World Mental Health Day
10 October 2024
Long-Term Game: NovaMedica Experts at the Pharma Marketing Conference
10 October 2024
NovaMedica in the TOP-1000 Russian Managers Rating
28 September 2024
Federal Center for Animal Health develops 13 new veterinary vaccines
22 October 2024
Haemophilia treatment with new delivery method approved
22 October 2024
Immunotherapy treatment enhances lymphoma survival, landmark study shows
21 October 2024
The Russian Ministry of Health initiates the creation of a list of key drugs
21 October 2024